Dyax Corp. and Novellus Biopharma AG Announce Partnership to Develop and Commercialize KALBITOR® (ecallantide) for Hereditary Angioedema (HAE) and Other Angioedema Indications in Latin America
Published: Jan 31, 2013
BURLINGTON, Mass. & BOGOTA, Colombia--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a developer of novel biotherapeutics for unmet medical needs, and Novellus Biopharma AG (Novellus) announced today a strategic partnership for the development and commercialization of KALBITOR® (ecallantide) for the treatment of hereditary angioedema (HAE) and other angioedema indications in select regions in Latin America, including Argentina, Brazil, Chile, Colombia, Mexico and Venezuela. KALBITOR is marketed in United States for the treatment of acute attacks of HAE in patients 16 years of age and older.